VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2021 | RxPONDER: is it all OFS?

Michael Gnant, MD, Medical University of Vienna, Vienna, Austria, provides a summary of a debate held during the San Antonio Breast Cancer Symposium looking at the results of the RxPONDER study (NCT01272037), which evaluated whether chemotherapy could be spared in women with node-positive early-stage breast cancer based on OncoType Dx ® score, and whether the results are a response to ovarian function suppression (OFS). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter